Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 14;7(7):CD007733.
doi: 10.1002/14651858.CD007733.pub3.

Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)

Arash Afshari  1 , Anders Bastholm Bille, Mikkel Allingstrup
Affiliations
Review

Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)

Arash Afshari et al. Cochrane Database Syst Rev. .

Abstract

Background: Acute respiratory distress syndrome (ARDS) is a critical condition that is associated with high mortality and morbidity. Aerosolized prostacyclin has been used to improve oxygenation despite the limited evidence available so far.This review was originally published in 2010 and updated in 2017.

Objectives: To assess the benefits and harms of aerosolized prostacyclin in adults and children with ARDS.

Search methods: In this update, we searched CENTRAL (2017, Issue 4); MEDLINE (OvidSP), Embase (OvidSP), ISI BIOSIS Previews, ISI Web of Science, LILACS, CINAHL (EBSCOhost), and three trials registers. We handsearched the reference lists of the latest reviews, randomized and non-randomized trials, and editorials, and cross-checked them with our search of MEDLINE. We contacted the main authors of included studies to request any missed, unreported or ongoing studies. The search was run from inception to 5 May 2017.

Selection criteria: We included all randomized controlled trials (RCTs), irrespective of publication status, date of publication, blinding status, outcomes published or language. We contacted trial investigators and study authors to retrieve relevant and missing data.

Data collection and analysis: Three authors independently abstracted data and resolved any disagreements by discussion. Our primary outcome measure was all-cause mortality. We planned to perform subgroup and sensitivity analyses to assess the effect of aerosolized prostacyclin in adults and children, and on various clinical and physiological outcomes. We assessed the risk of bias through assessment of methodological trial components and the risk of random error through trial sequential analysis.

Main results: We included two RCTs with 81 participants.One RCT involved 14 critically ill children with ARDS (very low quality of evidence), and one RCT involved 67 critically ill adults (very low quality evidence).Only one RCT (paediatric trial) provided data on mortality and found no difference between intervention and control. However, this trial was eligible for meta-analysis due to a cross-over design.We assessed the benefits and harms of aerosolized prostacyclin. One RCT found no difference in improvement of partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio (mean difference (MD) -25.35, 95% confidence interval (CI) -60.48 to 9.78; P = 0.16; 67 participants, very low quality evidence).There were no adverse events such as bleeding or organ dysfunction in any of the included trials. Due to the limited number of RCTs, we were unable to perform the prespecified subgroup and sensitivity analyses or trial sequential analysis.

Authors' conclusions: We are unable to tell from our results whether the intervention has an important effect on mortality because the results were too imprecise to rule out a small or no effect. Therefore, no current evidence supports or refutes the routine use of aerosolized prostacyclin for people with ARDS. There is an urgent need for more RCTs.

PubMed Disclaimer

Conflict of interest statement

AA: none known.

ABB: none known.

MA: none known.

Figures

1
1
Study flow diagram.
2
2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD007733.pub2

References

References to studies included in this review

Dahlem 2004 {published and unpublished data}
    1. Dahlem P, Aalderen WM, Neef M, Dijkgraaf MG, Bos AP. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Critical Care Medicine 2004;32(4):1055‐60. [PUBMED: 15071401] - PubMed
Siddiqui 2013 {published and unpublished data}
    1. Siddiqui S, Salahuddin N, Zubair S, Yousuf M, Azam I, Gilani AH. Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS ‐ a randomised clinical trial. Open Journal of Anesthesiology 2013;3(2):109‐15. [DOI: 10.4236/ojanes.2013.32027] - DOI

References to studies excluded from this review

Abraham 1996 {published data only}
    1. Abraham E, Park YC, Covington P, Conrad SA, Schwartz M. Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo‐controlled, randomized, double‐blind, multicenter clinical trial. Critical Care Medicine 1996;24(1):10‐5. [PUBMED: 8565513] - PubMed
Abraham 1999 {published data only}
    1. Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy HN, et al. Liposomal prostaglandin E1 (TLC C‐53) in acute respiratory distress syndrome: a controlled, randomized, double‐blind, multicenter clinical trial. TLC C‐53 ARDS Study Group. Critical Care Medicine 1999;27(8):1478‐85. [PUBMED: 10470753 ] - PubMed
Ammar 2015 {published data only}
    1. Ammar MA, Bauer SR, Bass SN, Sasidhar M, Mullin R, Lam SW. Noninferiority of inhaled epoprostenol to inhaled nitric oxide for the treatment of ARDS. Annals of Pharmacotherapy 2015;49(10):1105‐12. [PUBMED: 26187741] - PubMed
Archer 1996 {published data only}
    1. Archer SL, Mike D, Crow J, Long W, Weir EK. A placebo‐controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996;109(3):750‐5. [PUBMED: 8617086] - PubMed
Bein 1994 {published data only}
    1. Bein T, Pfeifer M, Riegger GA, Taeger K. Continuous intraarterial measurement of oxygenation during aerosolized prostacyclin administration in severe respiratory failure. New England Journal of Medicine 1994;331(5):335‐6. [PUBMED: 8022461] - PubMed
Boeck 2012 {published data only}
    1. Boeck L, Tamm M, Grendelmeier P, Stolz D. Acute effects of aerosolized iloprost in COPD related pulmonary hypertension ‐ a randomized controlled crossover trial. PloS One 2012;7(12):e52248. [PUBMED: 23300624 ] - PMC - PubMed
Bone 1989 {published data only}
    1. Bone RC, Slotman G, Maunder R, Silverman H, Hyers TM, Kerstein MD, et al. Randomized double‐blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989;96(1):114‐9. [PUBMED: 2661155] - PubMed
    1. Silverman HJ, Slotman G, Bone RC, Maunder R, Hyers TM, Kerstein MD, et al. Effects of prostaglandin E1 on oxygen delivery and consumption in patients with the adult respiratory distress syndrome. Results from the prostaglandin E1 multicenter trial. The Prostaglandin E1 Study Group. Chest 1990;98(2):405‐10. [PUBMED: 2198140] - PubMed
    1. Slotman GJ, Kerstein MD, Bone RC, Silverman H, Maunder R, Hyers TM, et al. The effects of prostaglandin E1 on non‐pulmonary organ function during clinical acute respiratory failure. The Prostaglandin E1 Study Group. Journal of Trauma 1992;32(4):480‐8. [PUBMED: 1569622] - PubMed
Domenighetti 2001 {published data only}
    1. Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Critical Care Medicine 2001;29(1):57‐62. [PUBMED: 11176161] - PubMed
Dunkley 2013 {published data only}
    1. Dunkley KA, Louzon PR, Lee J, Vu S. Efficacy, safety, and medication errors associated with the use of inhaled epoprostenol for adults with acute respiratory distress syndrome: a pilot study. Annals of Pharmacotherapy 2013;47(6):790‐6. [PUBMED: 23656748 ] - PubMed
Eichelbrönner 1996 {published data only}
    1. Eichelbrönner O, Reinelt H, Wiedeck H, Mezödy M, Rossaint R, Georgieff M, et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock ‐ different effects on splanchnic oxygenation?. Intensive Care Medicine 1996;22(9):880‐7. [PUBMED: 8905421] - PubMed
Holcroft 1986 {published data only}
    1. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E(1) and survival in patients with the adult respiratory distress syndrome: a prospective trial. Seminars in Respiratory Medicine 1986;8 Suppl:40‐7. - PMC - PubMed
    1. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Annals of Surgery 1986;203(4):371‐8. [PUBMED: 3516085] - PMC - PubMed
Liu 2015 {published data only}
    1. Liu D, Luo G, Luo C, Wang T, Sun G, Hei Z. Changes in the concentrations of mediators of inflammation and oxidative stress in exhaled breath condensate during liver transplantation and their relations with postoperative ARDS. Respiratory Care 2015;60(5):679‐88. [PUBMED: 25628453 ] - PubMed
Meyer 1998 {published data only}
    1. Meyer J, Theilmeier G, Aken H, Bone HG, Busse H, Waurick R, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesthesia and Analgesia 1998;86(4):753‐8. [PUBMED: 9539597] - PubMed
NCT00981591 {published and unpublished data}
    1. NCT00981591. Inhaled iloprost as an adjunct to inhaled nitric oxide in pediatric critical care patients. clinicaltrials.gov/ct2/show/NCT00981591 Date first received: 18 September 2009.
Pappert 1995 {published data only}
    1. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995;82(6):1507‐11. [PUBMED: 7793662] - PubMed
Putensen 1998 {published data only}
    1. Putensen C, Hörmann C, Kleinsasser A, Putensen‐Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 1998;157(6 Pt 1):1743‐7. [PUBMED: 9620900] - PubMed
Rossignon 1990 {published data only}
    1. Rossignon MD, Khayat D, Royer C, Rouby JJ, Jacquillat C, Viars P. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double‐blind placebo‐controlled study on the activity of prostaglandin E1. Anesthesiology 1990;72(2):276‐81. [PUBMED: 2405741] - PubMed
Sawheny 2013 {published data only}
    1. Sawheny E, Ellis AL, Kinasewitz GT. Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS. Chest 2013;144(1):55‐62. [PUBMED: 23370599] - PubMed
Shoemaker 1986 {published data only}
    1. Shoemaker WC, Appel PL. Effects of prostaglandin E1 in adult respiratory distress syndrome. Surgery 1986;99(3):275‐83. [PUBMED: 3513357] - PubMed
Sood 2014 {published and unpublished data}
    1. Sood B, Keszler M, Garg M, Klein JM, Ohls R, Ambalavanan N, et al. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials 2014;15:486. [PUBMED: 25496504] - PMC - PubMed
Torbic 2013 {published data only}
    1. Torbic H, Szumita PM, Anger KE, Nuccio P, LaGambina S, Weinhouse G. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. Journal of Critical Care 2013;28(5):844‐8. [PUBMED: 23683572] - PubMed
Torbic 2016 {published data only}
    1. Torbic H, Szumita PM, Anger KE, Nuccio P, Lagambina S, Weinhouse G. Clinical and economic impact of formulary conversion from inhaled Flolan to inhaled veletri for refractory hypoxemia in critically ill patients. Annals of Pharmacotherapy 2016;50(2):106‐12. [PUBMED: 26668204] - PubMed
Van Heerden 1996 {published data only}
    1. Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS ‐ a pilot study. Anaesthesia and Intensive Care 1996;24(5):564‐8. [PUBMED: 8909667] - PubMed
Van Heerden 2000 {published data only}
    1. Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose‐response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000;117(3):819‐27. [PUBMED: 10713012] - PubMed
Vassar 1991 {published data only}
    1. Vassar MJ, Fletcher MP, Perry CA, Holcroft JW. Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients: a prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation. Prostaglandins, Leukotrienes and Essential Fatty Acids 1991;44(4):223‐31. [PUBMED: 1667693] - PubMed
Vincent 2001 {published data only}
    1. Vincent JL, Brase R, Santman F, Suter PM, McLuckie A, Dhainaut JF, et al. A multi‐centre, double‐blind, placebo‐controlled study of liposomal prostaglandin E1 (TLC C‐53) in patients with acute respiratory distress syndrome. Intensive Care Medicine 2001;27(10):1578‐83. [PUBMED: 11685297] - PubMed
Walmrath 1995 {published data only}
    1. Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. American Journal of Respiratory and Critical Care Medicine 1995;151(3 Pt 1):724‐30. [PUBMED: 7881662] - PubMed
Walmrath 1996 {published data only}
    1. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 1996;153(3):991‐6. [PUBMED: 8630585] - PubMed
Zwissler 1996 {published data only}
    1. Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 1996;154(6 Pt 1):1671‐7. [PUBMED: 8970353] - PubMed

Additional references

Adhikari 2004
    1. Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004477.pub2] - DOI - PMC - PubMed
Adhikari 2007
    1. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta‐analysis. BMJ 2007;334(7597):779. [PUBMED: 17383982] - PMC - PubMed
Altman 2003
    1. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. [PUBMED: 12543843] - PMC - PubMed
Anderson 2003
    1. Anderson MR. Update on pediatric acute respiratory distress syndrome. Respiratory Care 2003;48(3):261‐76. [PUBMED: 12667276] - PubMed
Angus 2001
    1. Angus DC, Musthafa AA, Clermont G, Griffin MF, Linde‐Zwirble WT, Dremsizov TT, et al. Quality‐adjusted survival in the first year after the acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 2001;163(6):1389‐94. [PUBMED: 11371406] - PubMed
Barrington 2007
    1. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD000509.pub3] - DOI - PubMed
Bernard 1994
    1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American‐European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. American Journal of Respiratory and Critical Care Medicine 1994;149(3 Pt 1):818‐24. [PUBMED: 7509706] - PubMed
Brok 2009
    1. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. Journal of Clinical Epidemiology 2009;38(1):287‐98. [PUBMED: 18824466] - PubMed
Chan 2004
    1. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457‐65. [PUBMED: 15161896] - PubMed
Dahlem 2003
    1. Dahlem P, Aalderen WM, Hamaker ME, Dijkgraaf MG, Bos AP. Incidence and short‐term outcome of acute lung injury in mechanically ventilated children. European Respiratory Journal 2003;22(6):980‐5. [PUBMED: 14680089] - PubMed
Dahlem 2007
    1. Dahlem P, Aalderen WM, Bos AP. Pediatric acute lung injury. Paediatric Respiratory Reviews 2007;8(4):348‐62. [PUBMED: 18005903] - PubMed
Dickersin 1990
    1. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263(10):1385‐9. [PUBMED: 2406472] - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. [PUBMED: 9310563] - PMC - PubMed
Flori 2005
    1. Flori HR, Glidden DV, Rutherford GW, Matthay MA. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality. American Journal of Respiratory and Critical Care Medicine 2005;171(9):995‐1001. [PUBMED: 15618461] - PubMed
Fröhlich 2013
    1. Fröhlich S, Murphy N, Ryan D, Boylan J. Acute respiratory distress syndrome: current concepts and future directions. Anaesthesia and Intensive Care 2013;41(4):463‐72. [PUBMED: 23808504] - PubMed
Fuller 2015
    1. Fuller BM, Mohr NM, Skrupky L, Fowler S, Kollef MH, Carpenter CR. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta‐analysis. Chest 2015;147(6):1510‐22. [PUBMED: 25742022] - PMC - PubMed
Gebistorf 2016
    1. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database of Systematic Reviews 2016, Issue 6. [DOI: 10.1002/14651858.CD002787.pub3] - DOI - PMC - PubMed
GRADEpro [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2015.
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [PUBMED: 12958120] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hill 2015
    1. Hill NS, Preston IR, Roberts KE. Inhaled therapies for pulmonary hypertension. Respiratory Care 2015;60(6):794‐802. [PUBMED: 26070575 ] - PubMed
Hutton 2000
    1. Hutton JL, Williamson PR. Bias in meta‐analysis due to outcome variable selection within studies. Journal of the Royal Statistical Society. Series C, Applied Statistics 2000;49(3):359‐70. [DOI: 10.1111/1467-9876.00197] - DOI
Jain 2006
    1. Jain R, DalNogare A. Pharmacological therapy for acute respiratory distress syndrome. Mayo Clinic Proceedings 2006;81(2):205‐12. [PUBMED: 16471076] - PubMed
Keus 2009
    1. Keus F, Wetterslev J, Gluud C, Gooszen HG, Laarhoven CJ. Robustness assessments are needed to reduce bias in meta‐analyses including zero‐event randomized trials. American Journal of Gastroenterology 2009;104(3):546‐51. [PUBMED: 19262513 ] - PubMed
Lan 1983
    1. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659‐63. [uame‐roche.com/public/web/images/bibliografia/discrete_sequential_boundaries....
Linko 2009
    1. Linko R, Okkonen M, Pettilä V, Perttilä J, Parviainen I, Ruokonen E, et al. Acute respiratory failure in intensive care units. FINNALI: a prospective cohort study. Intensive Care Medicine 2009;35(8):1352‐61. [PUBMED: 19526218] - PubMed
Luhr 1999
    1. Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, et al. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. American Journal of Respiratory and Critical Care Medicine 1999;159(6):1849‐61. [PUBMED: 10351930] - PubMed
MacCallum 2005
    1. MacCallum NS, Evans TW. Epidemiology of acute lung injury. Current Opinion in Critical Care 2005;11(1):43‐9. [PUBMED: 15659944] - PubMed
Moloney 2003
    1. Moloney ED, Evans TW. Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. European Respiratory Journal 2003;21(4):720‐7. [PUBMED: 12762363] - PubMed
Phua 2009
    1. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, et al. Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. American Journal of Respiratory and Critical Care Medicine 2009;179(3):220‐7. [PUBMED: 19011152] - PubMed
Piantadosi 2004
    1. Piantadosi CA, Schwartz DA. The acute respiratory distress syndrome. Annals of Internal Medicine 2004;141(6):460‐70. [PUBMED: 15381520] - PubMed
Pogue 1997
    1. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials 1997;18(6):580‐93. [PUBMED: 9408720] - PubMed
Pogue 1998
    1. Pogue J, Yusuf S. Overcoming the limitations of current meta‐analysis of randomized controlled trials. Lancet 1998;351(9095):45‐52. [PUBMED: 9433436] - PubMed
Ranieri 2012
    1. ARDS Definition Task Force, Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307(23):2526‐33. [PUBMED: 22797452] - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rubenfeld 2005
    1. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al. Incidence and outcomes of acute lung injury. New England Journal of Medicine 2005;353(16):1685‐93. [PUBMED: 16236739] - PubMed
Rücker 2008
    1. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine 2008;27(5):746‐63. [PUBMED: 17592831] - PubMed
Schuster 2008
    1. Schuster KM, Alouidor R, Barquist ES. Nonventilatory interventions in the acute respiratory distress syndrome. Journal of Intensive Care Medicine 2008;23(1):19‐32. [PUBMED: 18230633] - PubMed
Siobal 2003
    1. Siobal MS, Kallet RH, Pittet JF, Warnecke EL, Kraemer RW, Venkayya RV, et al. Description and evaluation of a delivery system for aerosolized prostacyclin. Respiratory Care 2003;48(8):742‐53. [PUBMED: 12890294] - PubMed
Siobal 2004
    1. Siobal M. Aerosolized prostacyclins. Respiratory Care 2004;49(6):640‐52. [PUBMED: 15165299] - PubMed
TenHoor 2001
    1. TenHoor T, Mannino DM, Moss M. Risk factors for ARDS in the United States: analysis of the 1993 National Mortality Followback Study. Chest 2001;119(4):1179‐84. [PUBMED: 11296187] - PubMed
Thorlund 2009
    1. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology 2009;38(1):276‐86. [PUBMED: 18824467] - PubMed
TSA 2010 [Computer program]
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial Sequential Analysis, version 0.8. Copenhagen: Copenhagen Trial Unit, 2010.
Vohwinkel 2015
    1. Vohwinkel C, Hoegl S, Eltzschig H. Hypoxia signaling during acute lung injury. Journal of Applied Physiology (Bethesda, Md. : 1985) 2015;119(10):1157‐63. [PUBMED: 25977449] - PMC - PubMed
Ware 2000
    1. Ware LB, Matthay MA. The acute respiratory distress syndrome. New England Journal of Medicine 2000;342(18):1334‐49. [PUBMED: 10793167] - PubMed
Wetterslev 2008
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75. [PUBMED: 18083463] - PubMed
Wetterslev 2009
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology 2009;9:86. [PUBMED: 20042080] - PMC - PubMed
Wetzel 1995
    1. Wetzel RC. Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator. Anesthesiology 1995;82(6):1315‐7. [PUBMED: 7793644] - PubMed
Zimmerman 2009
    1. Zimmerman JJ, Akhtar SR, Caldwell E, Rubenfeld GD. Incidence and outcomes of pediatric acute lung injury. Pediatrics 2009;124(1):87‐95. [PUBMED: 19564287] - PubMed

References to other published versions of this review

Afshari 2009
    1. Afshari A, Brok J, Møller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007733] - DOI - PubMed
Afshari 2010
    1. Afshari A, Brok J, Møller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD007733; PUBMED: 20687093] - DOI - PubMed

LinkOut - more resources